The California-based precision oncology firm Guardant Health has struck a deal to advertise its vary of liquid and tissue biopsy exams for most cancers screening throughout the Center East and North African markets.
Partnering with the multinational pharmaceutical firm Hikma Pharmaceuticals, the partnership plans to market Guardant Well being’s recurrence monitoring and tumour mutation profiling throughout all strong cancers in international locations all through the area.
The partnership consists of Guardant Well being’s merchandise resembling Defend take a look at for most cancers screening and detection, Guardant Reveal for illness detection,Guardant360 and its variant TissueNext, which is meant for genomic profiling throughout all strong cancers.
Simranjit Singh, Guardant Well being Europe, the Center East and Africa (AMEA) CEO, mentioned: “In the present day, an rising variety of sufferers with most cancers are being detected on the superior stage, making it extra essential to match these sufferers to acceptable therapies in a well timed method. In the end, our purpose is to make most cancers screening straightforward and efficient in order that we are able to detect most cancers earlier when it’s most treatable.”
It comes amid a sequence of worldwide expansions for Guardant Well being, with the corporate introducing its blood-based colorectal most cancers (CRC) screening take a look at Defend in South Korea in November 2023.
In Could final yr, the corporate additionally expanded into Singapore, receiving approval from the nation’s Well being and Sciences Authority to market its Guardant360 CDx liquid biopsy take a look at for sufferers with superior strong tumours.
Entry probably the most complete Firm Profiles
available on the market, powered by GlobalData. Save hours of analysis. Achieve aggressive edge.
Firm Profile – free
Your obtain e mail will arrive shortly
We’re assured in regards to the
high quality of our Firm Profiles. Nevertheless, we wish you to take advantage of
determination for what you are promoting, so we provide a free pattern that you would be able to obtain by
submitting the beneath kind
Hikma’s government vice chairman Mazen Darwazah mentioned: “Our partnership with Guardant Well being provides next-generation sequencing diagnostics that may probably remodel most cancers care within the Center East and North Africa bringing hope to sufferers going through this difficult journey. We’re excited to associate with Guardant Well being, as their providing will help sufferers in any respect phases of the illness.”
In Could of 2021, Guardant Well being reported that its first blood-only liquid biopsy for detecting minimal residual illness (MRD) was in a position to determine stage I-IV colorectal most cancers (CRC) sufferers with elevated danger of recurrence, with larger sensitivity than earlier iterations.